PL3267983T3 - Sposoby leczenia proteinopatii - Google Patents

Sposoby leczenia proteinopatii

Info

Publication number
PL3267983T3
PL3267983T3 PL16711088.1T PL16711088T PL3267983T3 PL 3267983 T3 PL3267983 T3 PL 3267983T3 PL 16711088 T PL16711088 T PL 16711088T PL 3267983 T3 PL3267983 T3 PL 3267983T3
Authority
PL
Poland
Prior art keywords
methods
treating proteinopathies
proteinopathies
treating
Prior art date
Application number
PL16711088.1T
Other languages
English (en)
Inventor
Seng H. Cheng
Lamya Shihabuddin
Sergio Pablo SARDI
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of PL3267983T3 publication Critical patent/PL3267983T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
PL16711088.1T 2015-03-10 2016-03-09 Sposoby leczenia proteinopatii PL3267983T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562131071P 2015-03-10 2015-03-10
PCT/US2016/021512 WO2016145046A1 (en) 2015-03-10 2016-03-09 Methods for treating proteinopathies

Publications (1)

Publication Number Publication Date
PL3267983T3 true PL3267983T3 (pl) 2024-05-13

Family

ID=55587378

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16711088.1T PL3267983T3 (pl) 2015-03-10 2016-03-09 Sposoby leczenia proteinopatii

Country Status (17)

Country Link
US (2) US20180036295A1 (pl)
EP (2) EP3267983B1 (pl)
JP (2) JP6990110B2 (pl)
KR (1) KR20170123329A (pl)
CN (1) CN107872976A (pl)
AU (1) AU2016229826A1 (pl)
CA (1) CA2978883A1 (pl)
EA (1) EA201791993A1 (pl)
ES (1) ES2973101T3 (pl)
HK (1) HK1244217A1 (pl)
HU (1) HUE065628T2 (pl)
IL (1) IL254393A0 (pl)
MX (1) MX2017011598A (pl)
PL (1) PL3267983T3 (pl)
PT (1) PT3267983T (pl)
TW (1) TW201642855A (pl)
WO (1) WO2016145046A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
CN110891565A (zh) * 2017-06-19 2020-03-17 凯诺斯医药公司 α-突触核蛋白的调控剂
TWI644673B (zh) * 2017-07-27 2018-12-21 百朗克股份有限公司 頭孢曲松的用途
SG11202107844UA (en) * 2019-02-04 2021-08-30 Genzyme Corp Methods for treating symptoms and disorders associated with lysosomal storage diseases
PT3920912T (pt) 2019-02-04 2025-09-09 Genzyme Corp Tratamento de ciliopatias usando inibidores da glucosilceramida sintase (gcs)
ES3058346T3 (es) * 2019-11-15 2026-03-10 Yuhan Corp Derivados que tienen un resto 2,3-dihidro-1H-indeno o 2,3-dihidrobenzofurano o una sal farmacéuticamente aceptable de mismo y composiciones farmacéuticas que comprenden los mismos
IL295255A (en) * 2020-02-03 2022-10-01 Genzyme Corp Methods for treating neurological symptoms associated with lysosomal storage diseases
EP4110317B1 (en) 2020-02-28 2025-11-19 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
US12624011B2 (en) * 2020-03-17 2026-05-12 Sumitomo Pharma Co., Ltd. Oxadiazole derivative
KR20230005168A (ko) * 2020-03-23 2023-01-09 프락시스 프리시젼 메디신즈, 인크. Kcnt1 억제제 및 사용 방법
IL300090A (en) * 2020-07-24 2023-03-01 Genzyme Corp Pharmaceutical preparations containing VENGLUSTAT
US20230372313A1 (en) * 2020-07-30 2023-11-23 Genzyme Corporation Methods for reducing glycosphingolipid concentration in brain tissue and methods of treatment of neurodegenerative diseases involving the same
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
CN120417900A (zh) 2022-12-01 2025-08-01 建新公司 文鲁司他与cyp3a4的强或中度抑制剂的组合
TW202606667A (zh) 2024-06-17 2026-02-16 美商健臻公司 使用葡萄糖神經醯胺合成酶抑制劑治療患有肝損傷之受試者的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US195A (en) 1837-05-15 Machine fob cutting and dressing stone
US4683A (en) 1846-08-08 waring and richard e
BE640616A (pl) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
LT2685986T (lt) * 2011-03-18 2020-03-10 Genzyme Corporation Gliukozilceramido sintazės slopiklis
AU2012272815B2 (en) * 2011-06-22 2017-09-07 The General Hospital Corporation Treatment of proteinopathies
MA37975B2 (fr) * 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide

Also Published As

Publication number Publication date
HUE065628T2 (hu) 2024-06-28
US20200197374A1 (en) 2020-06-25
KR20170123329A (ko) 2017-11-07
JP7374149B2 (ja) 2023-11-06
EP3267983B1 (en) 2023-12-20
HK1244217A1 (zh) 2018-08-03
EA201791993A1 (ru) 2017-12-29
JP6990110B2 (ja) 2022-02-10
TW201642855A (zh) 2016-12-16
JP2021119185A (ja) 2021-08-12
EP3267983A1 (en) 2018-01-17
EP4349408A3 (en) 2024-06-19
AU2016229826A1 (en) 2017-10-26
EP4349408A2 (en) 2024-04-10
JP2018507886A (ja) 2018-03-22
MX2017011598A (es) 2017-12-20
PT3267983T (pt) 2024-03-12
WO2016145046A1 (en) 2016-09-15
IL254393A0 (en) 2017-11-30
CA2978883A1 (en) 2016-09-15
ES2973101T3 (es) 2024-06-18
US20180036295A1 (en) 2018-02-08
CN107872976A (zh) 2018-04-03

Similar Documents

Publication Publication Date Title
IL304252A (en) Cancer treatment methods
IL289947A (en) A method for treating cancer
IL279308A (en) Methods for the treatment of heptidine-mediated disorders
ZA201705673B (en) Methods for treating skin
ZA201706616B (en) Method for treating cancer
SG11201708861VA (en) Methods for treating cancer
IL254393A0 (en) Methods for treating diseases associated with pathological changes in protein
PT4001311T (pt) Combinações anti-pd-l1/pd-1 para tratamento de tumores
IL257691A (en) A method for treating cancer
IL256836B (en) Methods for treating cancer using apilimod
IL258988A (en) Methods for treating epilepsy
GB201500427D0 (en) Method
IL255022A0 (en) Cancer treatment methods
IL249936A0 (en) Methods for treating hypotension
GB201501941D0 (en) Method
SG11201605070UA (en) Novel methods for treating cancer
IL255018A0 (en) Cancer treatment methods
SG10201508795XA (en) Method for treating cancer
GB201501565D0 (en) Method
IL255016A0 (en) Cancer treatment methods
PT3250218T (pt) Péptido natkide para o tratamento da obesidade
ZA201607068B (en) Methods for treating hypersomnia
SG11201706885RA (en) Novel treatment method
GB201502409D0 (en) Method
IL249616A0 (en) Methods for treating inflammation